Comparative efficacy of acid-suppressive and gastroprotective agents in patients with coronary heart disease on antiplatelet therapy: A systematic review and network meta-analysis.
Zhang Yujie Y, Zhang Junyan J, Fan Xiaoli X, Ao Xiaoyan X et al.
Gastrointestinal complications remain an important clinical concern in patients with coronary heart disease (CHD) receiving antiplatelet therapy, and the comparative effectiveness of available acid-suppressive and gastroprotective strategies in this population remains uncertain. To compare the efficacy of acid-suppressive agents and gastric mucosal protectants for preventing peptic ulcer occurrence and gastrointestinal bleeding in patients with CHD receiving antiplatelet therapy. Systematic review and network meta-analysis of randomized controlled trials. PubMed, Embase, the Cochrane Library, and Ovid MEDLINE were searched from inception to May 29, 2024. Eligible trials enrolled patients receiving antiplatelet therapy, predominantly low-dose aspirin or dual antiplatelet therapy, and compared PPIs, H2RAs, P-CAB, gastric mucosal protectants, or placebo. Relative risks were synthesized using random-effects network meta-analysis, with assessment of risk of bias, inconsistency, transitivity, and small-study effects. Twenty randomized controlled trials were included. Acid-suppressive agents were generally more effective than gastroprotective agents in preventing gastrointestinal complications. For peptic ulcer occurrence, the estimated RRs versus placebo were 0.05 for vonoprazan, 0.14 for PPIs, and 0.48 for famotidine, whereas gastroprotective agents showed less consistent protective effects. For gastrointestinal bleeding, vonoprazan also showed favorable trends. However, the evidence for P-CAB was based on a limited number of trials, and its apparent advantage over PPIs should therefore be interpreted cautiously. Acid-suppressive therapies may be preferable to gastroprotective agents for preventing gastrointestinal injury in patients with CHD receiving antiplatelet therapy. P-CAB ranked highest in the current network, but this finding should be considered hypothesis-generating until confirmed by adequately powered direct comparative trials against PPIs.